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Abstract
Background: Anal squamous intraepithelial lesions (ASIL), strongly related to human papilloma virus (HPV) infection, is more prevalent among men who have sex with men (MSM). However, no such data are available for Pakistan
yet, and neither HPV vaccination nor anal-cytology screening is implemented in Pakistan. The purpose of this first
ever study was to assess the prevalence of HPV-related anal cytological abnormalities among MSM and transgender
women living with and without HIV infection in Pakistan.
Methods: We conducted a cross-sectional study from March 2016 to November 2017 at sexual health centers run
by the Perwaaz Trust and the National AIDS Control Program in Karachi. The study enrolled MSM and transgender
women aged greater-than-and-equal-to-18-years who reported anal sex in the preceding 6 months. We collected
two anal samples for liquid-based cytology and HPV type testing by PCR, and socio-demographic and behavioral data
were collected through face-to face interviews. ASIL and its associations with biological and behavioral risk factors
were analyzed through Cox regression for prevalence ratios (PR) and corresponding 95% confidence intervals (CIs).
Results: Out of 271 qualifying participants, 79% were MSM and 21% transgender women. The mean age was 28.8
(± 8) years. Almost 35% (93/271) of the study population had ASIL detected, ASIL was significantly more common
among participants living with HIV than in HIV negative ((50/118) 42.4%; vs. (43/153) 28.1%) (p ≤ 0.001). Among ASIL,
66% (61/93) had low-grade squamous intraepithelial lesions (LSIL), and 3.6% (3/93) had high-grade squamous intraepithelial lesions (HSIL). The overall, HPV16 positivity was 35.5% (33/93) among all abnormal anal lesions and all 3 HSIL
were HPV16 positive, however, HPV16 positivity could show its association with ASIL detection in univariate model
only (PRcrude: 2.11(1.39–3.18)). Moreover, any HR-HPV type (PR 3.04; 95% CI 1.75–5.26), concurrent sexually transmitted
infection (STI) (2.13; (1.28–3.55)) and HIV + /HPV + coinfection (1.75; (1.07–2.88)) remained independently associated
with ASIL in the multivariate model.
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Conclusions: Abnormal anal cytology among MSM and transgender is prevalent enough to consider optimal
screening regimens. Further studies are required to see if periodic anal cytology can be made part of HIV care and
treatment programs among MSM in Pakistan.
Keywords: Anal cytology, Anal cancer, ASIL, LSIL, HSIL, HPV infection, Anal Pap smear, HIV, Men who have sex with
men, MSM, STI, Transgender, Pakistan

Background
Persistent infection with Human Papillomavirus (HPV)—
predominantly high-risk HPV type 16 is the major cause
of anal cancer [1] Over the past decade, the global incidence of anal squamous cell carcinoma (SCC), is rare
and stable in the general population [2] however, it is
20 times more likely to occur in men who have sex with
men (MSM) [3, 4] compared to heterosexual men [5].
The risk of anal cancer is highest in MSM living with HIV
[4, 6–8], other individuals living with HIV [9], immunosuppressed individuals [10], and women with history of
HPV associated anogenital dysplasia [11]. The reported
incidence of anal cancer in general population is 1.8 per
100,000 persons [12], in MSM it ranges between 19–35
cases per 100,000 and up to 88–131/100,000 in MSM
living with HIV, i.e., more than 70 times more common
than in the general population [9, 13–15]. The increasing
incidence of anal cancer can be associated with increases
in the number of sexual partners and a higher prevalence
of anal sex in the past few decades [16, 17].
Anal squamous intraepithelial lesions (ASIL) are the
putative precursors of anal cancer, similar to cervical squamous intraepithelial lesions (CSILs) in cervical
cancer [18–22]. ASIL spans from low grade squamous
intraepithelial lesions (LSIL) to high grade squamous
intraepithelial lesions (HSIL) [23]. Approximately 90% of
LSIL are caused by infection with low-risk HPV types 6
and 11 often clinically presenting as condyloma—genital
warts—while infections with high-risk HPV types 16 and
18 are associated with HSIL [24]. However, persistent
anal infection with both low-risk or high-risk HPVs and
related ASILs have been associated with an increased risk
for invasive anal cancer [24, 25]. Both people living with
HIV and MSM generally have a higher prevalence and
incidence of anal canal and perianal HSIL [21, 26]. The
impact of antiretroviral therapy (ART) for HIV appears
to be very limited in terms of reducing the risk of HSIL
or squamous cell cancer of the anal canal and perianal
region [27, 28].
Although there is a dearth of evidence-based uniform
screening recommendations as well as benefits verses
harm appraisals [29], however, recent research suggests
that anal Papanicolaou (Pap) screening may have utility
in preventing anal cancer [30–32], and is cost-effective
screening method for anal cancer prevention among

MSM [30, 33] Anal cytology can be used as a standard
screening tool for individuals at risk for anal cancer to
detect early stage ASIL as screening tests used for cervical cytology [24, 34, 35]. High levels of abnormal cytology have consistently been reported among previously
unscreened MSM both without (12–32%) and with (34–
58%) HIV [36–38] in various settings.
Anal cytology screening and preventive treatment programs for MSM have not yet been routinely adopted by
Pakistan for multiple reasons, including an absence of
local prevalence estimates, sufficient clinical expertise
and infrastructure and updated guidelines for the management of sexually transmitted infections (STI). To contribute evidence for future policy, prevention, screening
and management of the anal cancer burden in Pakistan,
we studied HPV, ASIL, STIs and associated socio-demographic, behavioral and clinical factors among MSM and
transgender women with and without HIV infection in
Karachi, Pakistan.

Methods
Study design and study setting

A cross-sectional study was conducted from March 2016
to November 2017 among MSM and transgender women
aged ≥ 18 years who reported having had anal sex in the
preceding 6 months. Using snowball and peer referral
sampling techniques, participants were recruited from a
male sexual health clinic run by community-based organization Perwaaz Trust in Karachi, Pakistan. The Perwaaz
Trust provides information and screening for STI, HIV
testing and counseling and other health care services to
MSM. We also recruited MSM and transgender women
with known HIV infection from a public sector HIV and
ART center run by the National AIDS Control Program of
the Government of Pakistan, situated at the Civil Hospital in Karachi. This is the largest (1900-bed) tertiary care
public hospital in Karachi and is a large public research
and teaching hospital attached to the Dow University
of Health Sciences, Karachi. Consecutive MSM and
transgender women living with HIV who were attending their quarterly visits at the center between March
2016 to November 2017 were invited to participate. The
study was approved by the Human Research Ethics Committee of The Aga Khan University (3612-CHS-ERC-15)
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and Dow University of Health Sciences Karachi Pakistan
(IRB-557/DUHS/APPROVAL/2015/84).
Study procedure

After explaining the purpose of the study and study procedures, potential participants were asked to provide
written informed consent. Thereafter, they were invited
to participate in a face-to-face interview and to provide
anal samples to detect the presence of HPV as well as any
cytological lesions in the perianal area and the anal canal.
A blood sample was obtained for confirmation of their
HIV status (through Architect HIV Ag–Ab Combo kit
by ABBOTT), viral load and CD4 + T-cell count (through
FACS Count TM flow cytometry, Becton Dickinson Co.,
Franklin Lakes, NJ, USA). Participants were informed
that they were free to interrupt the interview or withdraw
from the study at any time without any negative consequences in terms of clinical services provided to them.
Data collection

A validated structured questionnaire with 45 questions
was administered by the principal investigator (ME) and
a trained data collector in a confidential space to collect
information on participants’ socio-demographic characteristics, sexual behavior (the past 6 months), reproductive and medical history, HIV history, any anal disease
and any use of ART. The interview lasted for an average
of 35–40 min. To establish the validity of the questionnaire, pilot testing was done on 10% of the sample size.
A local panel of experts established content validity.
Internal consistency of the questions was established by
Cronbach’s alpha wherein values between 0.70 and 0.90
were obtained. Data were coded by the principal investigator (ME) and entered by two independent data operators. Data were validated and corrected for any disparity.
Frequencies were run on data for logical error checking and for any discrepancy, and study participants who
had given their consent to be contacted were contacted
through telephone or asked when visiting the study settings for correction of any errors.
Biological sample collection

In order to exclude the presence of any ano-genital warts,
all participants underwent an inspection of their external
genitalia and perianal area by a trained physician who
also collected an anal sample using a moistened sterile Dacron swab (Copan Diagnostics Inc, Corona, CA,
USA). The swab was inserted 3–5 cm into the anus without any direct visualization and then rotated against the
anal canal wall for a minute before being removed slowly
in a spiral fashion. Immediately after sampling, the swab
was inserted into 3 mL of a methanol-based fixative, a
sample transport medium (Universal Transport medium,
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Corona CA, USA), and transferred to a pathology laboratory for cytological assessment by two experienced
cytopathologists at the Sindh Institute of Urology and
Transplantation. About 0.5 ml of the cell suspension from
the collected sample was drawn with an adjuster and put
into a disposable Shandon EZ mega funnel for smear
preparation in a cytospin. Glass slides were labelled and
fixed into the megafunnel. The sample was centrifuged
at 1000 rpm for 10 min. After 10 min, the slides were
removed from the cytospin, fixed in alcohol and stained
with both hematoxylin and eosin (HE) stain and Papanicolaou stain. The anal cytology was classified using the
Bethesda criteria for cervical cytology [39]. Abnormal
cytology was classified as atypical squamous or epithelial
cell abnormalities, including atypical squamous cells of
undetermined significance (ASCUS), LSIL, atypical squamous cells that do not exclude high-grade lesions (ASCH) and HSIL [39].
HPV-testing was performed on anal PreservCyt® specimens using Polymerase Chain Reaction (PCR) for detection of low-risk (6/11) and high-risk (group 1) genotypes
(16/18/31/33/35/39/45/52/56/58/59).
Statistical analysis and study variables

In total, 298 men and transgender women were recruited,
out of which 27 (9.0%) were excluded from the cytological
analyses due to insufficient biological material and thus
omitted from the statistical analyses as well. Data analyses were performed using SPSS version 24.0 (Statistical
Package for Social Sciences TX, USA). The prevalence
of ASIL and 95% confidence intervals (CI) were calculated using the exact binomial method. The associations
between biological and behavioral risk factors (independent variables) and cytologically identified ASIL (dependent variable) were analyzed using Cox regression hazard
model algorithms with robust SEs to estimate prevalence
ratios (PRs) and corresponding 95% CI. Biological determinants included HIV status; anal STIs, i.e., gonorrhoea
(Neisseria gonorrhoeae), trichomonas and anal warts
diagnosed or reported in the last 6 months; and anal HPV
infection as determined by PCR. Anal symptoms including anal bleeding, itching or any pus discharge were
also considered. Behavioral factors included number of
sexual partners, consistent (always) condom use, smoking status (yes/no, if yes age at initiation; average number
of cigarettes per day < 10, between 10 and 20, > 10; and
were cigarettes filtered or unfiltered) and drinking alcohol (yes/no, if yes how many times; < 5 times, between 5
and 10, or more than 10 times/week) were also analyzed
for their association with the dependent variable ASIL. A
t-test was also performed to compare the mean number
of types of HPV infections between those with and without ASIL.
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Results
This study included a total of 118 participants living with
HIV and 153 without HIV in the final cytological and
statistical analyses. Those living with HIV were significantly older than HIV negative participants (30.9 versus
27.2; p ≤ 0.001), among PLWH 89.3% were on combination ART, 74.8% had recent CD4 count of more than 350
cells/μl) and nearly two-thirds (76.3%) had undetectable
HIV viral load at their last assessment. There were also
significant differences in the duration of sex work, number of sexual partners, receptive anal intercourse, and
inconsistent condom use at anal intercourse in the last
6 months between study participants living with versus
without HIV (Table 1).
HIV status (53.8% vs 38.1%; p = 0.014), age at sex work
initiation (15.6 vs 17.0 years p = 0.02), inconsistent condom use (74.7% vs 52.3% p = 0.001) and receptive anal
sex (95.8% vs 86.4% p = 0.01) were associated with greater
prevalence of ASIL detection (Table 2).
Cytologic assessment

Twenty-seven participants (9%) were excluded due to
inadequate sample cellularity making them insufficient
for cytologic assessment, leaving 271 participants (HIV
positive n = 118; HIV negative n = 153) for the cytological
and statistical analyses. Out of 271, a total of 93 (35.0%)
MSM and transgender women had any ASIL (ASCUS,
LSIL, ASC-H or HSIL) (Fig. 1). Participants living with
HIV were significantly more likely to have such an abnormality as compared to those who were HIV negative
((50/118) 42.4%; vs. (43/153) 28.1%) (p ≤ 0.001); (Fig. 2).
Age was not associated with the detection of cytological
abnormalities (p = 0.31). Just one HIV-negative participant had ASC-H (who had multiple HPV types: LR-HPV
6 & 11 and HR-HPV 35) while three (2.5%; 3/118) participants living with HIV had developed HSIL and all three
samples of HSIL were positive for HPV16. HIV infected
participants were infected with multiple HPV types than
HIV uninfected participants (p < 0.001) (Table 3).
The overall and type specific HPV infection

Overall HPV infection prevalence among study population was 66.4% (180/271). Study participants living with
HIV were significantly more infected with HPV (60%;
108/180) than participants living without HIV (40%;
72/180) (p value ≤ 0.001). Among 180 HPV positive participants, 83% (n = 149/180) had at least one HR-HPV
type among them. Overall HPV16-positivity among all
HPV positive was 35% (n = 63/180).
All participants with ASIL (n = 93) were HPV positive. Within ASIL, the most prevalent HPV types were
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HPV6/11 (39.8% (n = 37)) followed by HPV16 (35.5%
(n = 33), HPV35 (16.1%; n = 15) and HPV18 (15%; n = 14)
(Fig. 3) (Additional file 1: Table S1).
Abnormal anal cytology associated risk factors

The detection of ASIL was associated with type of HPV
infection, in particular HPV16 (PRcrude = 2.11, 95% CI
1.39–3.18), known as one of the high-risk types for cancer development, while HPV type 35 was the second
most common oncogenic type among study participants
and was associated with 59% increased prevalence of
ASIL detection ( PRcrude = 1.59, 95% CI 0.99–2.58). Participants living with HIV were more likely to have such an
abnormality as compared to those who were HIV negative (PRcrude = 2.33, 95% CI 1.36–2.41). However, all these
factors could not appear as an independent risk factor for
the greater prevalence of ASIL detection in the multivariate model.
Nevertheless,
having
any
HR-HPV
type
(16/18/31/33/35/45/52/58) (PR 3.04; 95% CI 1.75–5.26),
having another concurrent STI (PR; 2.13, 95% CI 1.28–
3.55) and being co-infected with both HPV and HIV (PR
1.75; 95% CI 1.07–2.88) were independently associated
with greater prevalence of ASIL detection while adjusting
for all other behavioral and sexual variables in the multivariate model (Table 4).

Discussion
This is the first study to report on the prevalence and risk
factors of any anal abnormal cytology among MSM and
transgender women in Pakistan. Not unexpectedly, we
found a strong association between concurrent high-risk
HPV, HIV infection and ASIL. The overall proportion
of MSM and transgender women with ASIL was 35%,
and those living with HIV were almost twice as likely to
have an abnormal cytology compared with HIV negative participants (42.4% versus 28.1%). Moreover, and as
expected, the prevalence and number of high-risk HPV
types was higher among those with an HIV infection,
including HPV16—the primary causal agent for anal cancer. The prevalence of estimates for ASIL in Pakistan are
consistent with previous studies from the Asian region
[40–42] and elsewhere [27, 34, 43–46]. However, the
ASIL rates that we found among in MSM in Pakistan are
slightly higher than what has been reported from India
(27.7%) [47], naturally influenced by study population
and sampling. To date, no South Asian studies among
MSM (including ours) have used high resolution anoscopy for histologic confirmation of the ASIL diagnosis,
which is considered to be the gold standard method [34].
Given that previous studies have shown that anal cytology is less sensitive when diagnosing ASIL compared to
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Table 1 Socio-demographic and lifestyle characteristics of MSM and Transgender women living with and without HIV also stratified
on HIV Status
Characteristics
Mean (± SD)

Study population
(N = 271)

HIV positive
(N = 118)

HIV negative
(N = 153)

p-value

28.8 (± 8.06)

30.9 (± 0.70)

27.0 (± 0.59)

< 0.001

< 25

90 (33.2)

23 (19.5)

67 (43.8)

< 0.001

25–29

84 (31.0)

38 (32.2)

46 (30.1)

30–34

36 (13.3)

19 (16.1)

17 (11.1)

≥ 35

61 (22.5)

38 (32.2)

23 (15.0)

211 (77.9)

79 (66.9)

132 (86.4)

53 (19.6)

34 (28.8)

19 (12.4)

7 (2.5)

05 (4.3)

02 (1.2)

Age categories in years n (% ages)

Marital status n (% ages)
Unmarried
Married
Separated/divorced

0.001

Smoking history
Current status: n (% ages)
  Yes

210 (77.5)

99 (83.9)

Age at smoking initiation in years mean (± SD)

16.5 (± 4.9)

15.5 (± 4.2)

111 (72.5)

118 (56.2)

50 (50.0)

68 (64.8)

65 (31.0)

34 (34.0)

31 (29.5)

18.0 (± 95.7)

0.02
< 0.001

Average number of cigarettes/day n (% ages)
  < 10
  10–20
  > 20
Duration of smoking in years Mean (± SD)

27 (12.8)
12.4 (± 8.5)

16 (16.0)
14.83 (± 9.0)

0.02

6(5.7)
10.15 (± 7.7)

< 0.001
< 0.001

  < 5 years n (%)

60 (28.6)

16 (16.0)

44 (39.6)

  5–10 years n (%)

51 (24.3)

21 (21.0)

30 (27.0)

  11–15 years n (%)

64 (30.5)

39 (39.0)

26 (23.4)

  > 15 years n (%)

35 (16.6)

24 (24.0)

11 (9.9)

58 (21.4)

34 (29.8)

24 (17.4)

156 (57.6)

55 (45.0)

101 (64.7)

Sexual behaviors
Sexual identity n (% ages)
  Bisexual
  Homosexual
  Transgender
Sex worker characteristics n (%)

57 (21.0)

33 (25.2)

24 (17.9)

215 (79.3)

91 (77.1)

124 (81.0)

0.008

0.43

Age first had sexual intercourse (in years) mean (± SD)

16.42 (± 4.7)

15.13 (± 3.8)

17.44 (± 5.1)

< 0.001

Duration of sex-work in-years mean (± SD)

12.42 (8.2)

15.76 (8.3)

9.8 (7.1)

< 0.001
< 0.001

Anal receptive sexual partners the last 6 months n (% ages)*
  < 25

23 (8.5)

4 (3.6)

19 (13.9)

  25–50

31 (11.4)

4 (3.6)

27 (19.7)

  51–100
   > 100

83 (30.6)

33 (30.0)

50 (36.5)

110 (40.6)

69 (62.7)

41 (29.9)

Condom use during anal receptive sex n (%)
  Consistent use

60 (22.1)

12(10.2)

48 (31.4)

163 (60.1)

95 (80.5)

68 (44.4)

48 (17.7)

11 (9.3)

37 (24.2)

  Mainly receptive

243 (89.7)

113 (95.8)

  Mainly insertive

28 (10.3)

5 (4.2)

23 (15.0)

0.004

160 (59.0)

88 (74.6)

72 (47.1)

< 0.001

205 (68.8)

104 (79.4)

101 (60.5)

< 0.001

  Inconsistent use
  Never use

< 0.001

Preferred role at anal sex

Presence of other STI

130 (85.02)

History of anal warts during previous 6 months
Yes

*Almost 80% of the study population was invloved in sex work. These categories of sexual partners in last six months i.e., (< 25), (25–50), (51–100), (> 100). Greater
number by and-large reflects their "clients"
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Table 2 Socio-demographic and lifestyle characteristics of MSM and transgender women living with and without HIV in Karachi,
Pakistan, by Anal Squamous Intraepithelial Lesions (ASIL) status
Characteristics

ASIL positive
(N = 93)

ASIL negative
(N = 178)

p-value

Age in years mean (± SD)

28.2 (± 7.8)

29.2 (± 7.8)

0.31

< 25

37 (39.8)

53 (26.8)

0.24

25–29

28 (30.1)

56 (31.5)

30–34

08 (8.6)

28 (15.7)

≥ 35

20 (21.5)

41 (23.0)

None

33 (35.1)

48 (27.0)

Middle school or less

27 (28.70)

41 (23.0)

High school or less

27 (29.8)

77 (43.2)

Graduate

6 (6.4)

12 (6.8)

Unmarried

74 (79.5)

137 (77.0)

Married

17 (18.3)

36 (20.2)

Separated/divorced

02 (2.2)

05 (2.8)

No

18 (18.9)

43 (24.4)

Yes

77 (81.1)

133 (75.6)

15.74 (± 4.2)

16.90 (± 4.2)

39 (54.2)
25 (34.7)
08 (11.1)

79 (59.4)
40 (30.1)
14 (10.5)

0.758

12.0 (± 8.6)

12.5 (± 8.6)

0.68

27 (28.4)
68 (71.6)

34 (19.3)
142 (80.7)

0.087

50 (53.8)
43 (46.2)

68 (38.1)
110(61.8)

0.014

17 (18.3)
46 (49.5)
30(32.2)

43 (24.4)
102 (57.3)
33 (18.5)

0.047

In years mean (± SD)

15.6 (± 4.4)

17.05 (± 4.8)

0.02

Duration of sex work in years mean (± SD)

12.5 (± 8.2)

12.15 (± 7.9)

0.70

9 (10.2)
6 (15.7)
26 (35.8)
47 (39.6)

14 (8.8)
25 (15.7)
57 (35.8)
63 (39.6)

0.079

8 (8.4)
71 (74.7)
16 (16.8)

52 (29.5)
92 (52.3)
32 (18.2)

< 0.001

91 (95.8)
4 (4.2)

152 (86.4)
24 (13.6)

0.01*

71 (74.7)
24 (25.3)

118 (67.0)
66 (33.0)

0.188

Age in categories n (% age)

Education n (% age)
0.113

Marital status n (% age)

Smoking status n (% age)

Age at smoking initiation in years; mean (± SD)

0.924

0.302
0.07

Average number of cigarettes/day n (% age)
< 10
10–20
> 20
Duration of smoking in years mean (± SD)
Alcohol drinking n (% age)
Yes
No
HIV status: n (% age)
Yes
No
Sexual identity: n (% age)
Bisexual
Homosexual
Transgender
Age first had sexual intercourse

Anal receptive sexual partners the last 6 months n (% age)
< 25
25–50
51–100
  > 100
Condom use during anal receptive sex n(% age)
Consistent use
Inconsistent use
Never
Preferred anal sex role n (% age)
Mainly receptive
Mainly insertive
History of anal warts in the previous 6 months n (% age)
Yes
No
*Fisher Exact test p-value
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suggests that a high proportion of MSM and transgender women in Pakistan are at substantial risk for developing anal cancer, in particular those with a concurrent
HIV infection. Of note, we found no HSIL cases among
HIV-negative participants, possibly partly because they
were relatively younger than MSM living with HIV

the gold standard anal biopsy with the histopathological results [34], the true prevalence of ASIL is likely to
be higher than found in our study. Furthermore, and as
a matter of concern, we found unexpectedly high proportions of anal cancer precursor lesions, i.e., ASCUS + (35.8%) among young HIV negative MSM. This

[CATEGORY NAME]
0.4%
ASCUS
10%

HSIL
1%
NILM (n=178)
LSIL

(n=61)

ASCUS (n=28)

LSIL
23%

ASC-H (n=1)
(n=3)

HSIL
[CATEGORY NAME]
65.68

Fig. 1 Distribution of anal squamous intraepithelial lesions (ASIL) among MSM and Transgender women. NILM negative for intraepithelial lesions or
malignancy, ASCUS atypical squamous cells of undetermined significance, LSIL low grade squamous intraepithelial lesions, ASC-H atypical squamous
cells do not exclude high-grade lesion, HSILs high grade squamous intraepithelial lesions

110

120
100
80

68

60
40

19

20

29

32

9

0

0

NILM

AS-CUS
HIV posive

LSIL

1

ASC-H

3
HSIL

HIV negave

Fig. 2 Distribution of anal squamous intraepithelial lesions (ASIL) stratified on HIV status among MSM and transgender women. NILM negative for
intraepithelial lesions or malignancy, ASCUS atypical squamous cells of undetermined significance, LSIL low grade squamous intraepithelial lesions,
ASC-H atypical squamous cells do not exclude high-grade lesion, HSILs high grade squamous intraepithelial lesions
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Table 3 Multiplicity of HPV types among any anal squamous intraepithelial lesions (ASIL) and HIV status among MSM and transgender
women in Karachi Pakistan
# of types
n (%)

All
N = 271

ASIL positive
n = 93

ASIL negative
n = 178

p-value
< 0.001*

None

92 (33.9)

0 (13.0)

92 (52.3)

One Type

64 (25.1)

32 (40.0)

32 (17.0)

HIV positive
n = 118

HIV negative
n = 153

p-value

15 (12.7)

77 (50.3)

< 0.001

27 (22.9)

23 (15.1)

Two types

84 (29.5)

40 (37.9)

44 (25.0)

47 (39.8)

35 (22.9)

Three types

27 (10.0)

20(21.1)

07 (4.0)

24 (20.3)

12 (7.8)

Four types

4 (1.5)

1 (1.1)

3 (1.7)

5 (4.3)

6 (3.9)

p-value < 0.001 *Fisher exact test p value

HPV 56
HPV 59
HPV 58
HPV 52
HPV 45
HPV 35
HPV 33
HPV 31
HPV 18
HPV 16
HPV 6/11
0

5

10

15

20

25

30

35

40

45

50

ALL N = (271)

HPV
6/11
30.6

23.2

14

4.8

4.4

15.1

5.2

5.2

5.2

7.4

5.2

ASIL negave (n=178)

22.7

14.8

12.7

2.3

4

11.4

2.8

2.8

4

4.5

4.5

ASIL posive (n=93)

45.3

35.5

15.1

9.5

5.3

16.1

9.5

9.5

7.4

12.6

6.3

HPV 16 HPV 18 HPV 31 HPV 33 HPV 35 HPV 45 HPV 52 HPV 58 HPV 59 HPV 56

Fig. 3 Distribution of HPV genotypes (in percentages) stratified on anal squmous intraepithelial lesions (ASIL) status among MSM and transgender
women

among our participants, but similar to previous findings
in an older HIV negative cohort with a mean age of 45
[21]. Although only HSIL is considered to be a precursor
of anal cancer, previous studies have shown that about
40% of HIV negative homo- or bisexual men with LSIL
at baseline progress to HSIL within only 2–4 years [21,
48]. Moreover, lesions diagnosed as ASC-US may also
hide squamous intraepithelial lesions [34, 49], and it is
recommended that all individuals with ASC-US or worse
on cytology undergo an accurate diagnostic evaluation
through HRA guided biopsy as it has high predictive
value for Anal Intraepithelial Neoplasia (AIN) [34, 48,
50]. Moreover, one third of ASC-US and LSIL reports are
associated with biopsy-diagnosed high-grade AIN [50].

Furthermore, it has been reported that AIN 2 and AIN
3 occurs in about 20% of patients with a negative cytology at baseline after an average of 2 years follow-up [34,
51–53].
Concurrent infection with more than one high-risk
HPV type has been associated with the presence of [28,
54, 55] or progression to AIN [24, 56]. The earlier work
of Palefsky et al. has linked having more than one HPV
type to a higher risk of progression [48] or incidence [57]
of anal squamous intraepithelial lesions. Similarly, a previous study on MSM living with HIV reported a double
risk of ASIL when three or more HPV types were present
compared to infection with only one type of HPV [58].
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Table 4 Factors associated with any abnormal anal cytology
(n = 93) among MSM and transgender women living with
(n = 118) and without HIV 9n = 153) in Karachi Pakistan
Determinants

Any abnormal
anal cytology
Crude PR (95%
CI)

p values

Any abnormal
anal cytology
Adjusted PR
(95% CI)

HIV status
Negative (ref.)

1.0

positive

2.33 (1.36–2.41)

< 0.001

Any HR-HPV types
No (ref.)

1.0

Yes

3.8 (2.25–6.51)

1.0
< 0.001

3.04 (1.75–5.26)

HPV type 16
No (ref.)

1.0

Yes

2.11 (1.39–3.18)

< 0.001

HPV type 35
No (ref.)

1.0

Ye

1.59 (0.99–2.58)

0.060

Other STIa
No (ref.)

1.0

Yes

2.77 (1.68–4.59)

1.0
< 0.001

2.13 (1.28–3.55)

< 0.001

1.75 (1.07–2.88)

HIV/HPV co-infection
No (ref.)

1.0

Yes

2.93 (1.92–4.45)

1.0

HIV/STIa co-infection
No (ref.)

1.0

Yes

2.04 (1.36–3.04)

0.001

Preferred anal sex role
Insertive (ref.)

1.0

Receptive anal sex

2.62 (0.96–7.13)

0.059

Condom use
Always (ref.)

1.0

Inconsistent use

3.27 (1.57–6.78)

0.002

Never use

2.50 (1.07–5.84)

0.034

Number of sex partners in past 6 monthsb
< 100 (ref.)

1.0

≥ 100

1.43 (0.94–2.17)

0.096

PR prevalence ratio
a

STIs included: gonorrhea and trichomonas

b

79.3% of our study participants were sex workers (Table 1)

MSM living with HIV had a significantly higher prevalence of high-risk HPV as well as multiple HPV types,
both low-and high-risk, compared to the HIV negative
participants. A possible explanation is HIV-induced
immunosuppression that results in a loss of HPV specific immunity, and reactivation or upregulation of a
preexisting HPV infection [58, 59]. A larger number of
HPV high-risk types among men living with HIV may
also indicate an inability to clear HPV infection [60]. A

higher risk of reinfection may also be a factor [61], as
seen in our study where MSM living with HIV reported
both more unprotected anal intercourse and receptive
anal sex preference compared to their counterparts
who were HIV negative.
Since infection with any HR-HPV type was associated
with threefold increase in risk of having any abnormal
anal cytology, it would be important to prospectively
monitor MSM and transgender women with high-risk
HPV infections and/or HPV/HIV coinfection to prevent invasive lesions and intervene on time to prevent
anal cancer, but also to learn more about the factors
that influence disease progression. We do know that
infection with HPV16 or HPV18 significantly increases
the risk of progression to high-grade lesions [55, 56],
and that concurrent STIs such as gonorrhea and trichomonas also significantly increase the risk of ASIL [60,
62, 63].
Other studies have indicated receptive anal intercourse
as a risk factor for anal lesions [62, 64, 65], but anal HPV
infection is not limited to men who have receptive sex
[66–68]; it can also be acquired during non-receptive
sexual activity. In the current study, abnormal anal cytology was equally prevalent among MSM regardless of anal
sex practice, receptive or non-receptive.
This study has some limitations. Firstly, due to lack of
equipment and clinicians trained in performing HRA in
Pakistan, our analysis of ASIL was based on anal cytology
and not on high-resolution anoscopy-driven biopsies, the
gold standard for determining disease severity. Awaiting
the dispersion of affordable advanced technology, liquidbased cytology, though less sensitive, can be used as a
screening tool in high-risk populations in resource-constrained settings as it is convenient, less invasive, cheaper,
less time-consuming and requires less expertise than
HRA [69]. The fact of the matter is that, recent development in the field of anal cancer screening research has
highlighted the potential role for anal Pap testing in providing long-term risk stratification for anal precursors in
HIV positive MSM [70]. The sensitivity of anal cytology
may also be improved by targeted repeated testing every
12 months among MSM who are HIV-positive but do not
yet have signs of anal squamous intraepithelial lesions, or
every 2–3 years for HIV-negative MSM [34, 71–73].
A second study limitation is the cross-sectional design,
undermining the evaluation of a causal relationship
between HPV and abnormal anal cytology, as well as the
impact of, i.e., concurrent STI. Thirdly, selection bias
may have been introduced by the recruitment of people
living with HIV from an ART center while the others
came from a community-based organization working for
MSM. However, the ART center is the only large center
located in Karachi and it represents all ethnic groups in
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Pakistan. Moreover, given the cultural and religious barriers related to homosexuality and transgender in Pakistan, recruiting our study subjects from an CBO was the
only feasible option.

Conclusion
To the best of our knowledge this is the first study from
Pakistan reporting anal HPV associated anal dysplasia in at-risk MSM and transgender women. One third
had abnormal anal cytology, and more than half were
infected with high-risk HPV. Our study findings indicate the pressing need for further large-scale studies to
document the efficacy of anal screening and to develop
national guidelines for management of MSM in general
and MSM living with HIV in particular. In the absence
of the proper infrastructure required for HRA, regular
screening with anal cytology of MSM and transgender
women may be considered as an initial step in national
HIV care and treatment program. Moreover, the benefit and harm analysis of such an approach can only be
explored through further screening trials.
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